Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 14 March 2014 | By Alexander Gaffney, RAC,
The European Commission's Scientific Committee on Emerging Newly Identified Health Risks (SCENIHR) -a scientific committee which conducts risk assessments for EU officials-has announced the publication of its initial draft assessment of the safety of metal-on-metal hip implants.
Metal-on-metal hip implants have been plagued with controversy around the globe. The devices, which claimed to be similar enough to predicate devices made with non-metal parts, have since been associated with high revision rates and the generation of metal (often chromium) shavings that have damaged the tissue of some patients. Most manufacturers have recalled the products from the market in the US, while influential researchers have called for the devices to be banned.
Globally, some regulators have advised patients against using the devices. In June 2012, a panel of experts convened by the US Food and Drug Administration indicated that they would recommend against their use, saying the devices' risks outweighed their benefits. The panel did not recommend removing the devices from the market, however. FDA later initiated a study regarding the causes of failure in hip implants, and also voted to institute new and more stringent regulatory requirements for the devices, which now require the submission of a premarket application (PMA).
In August 2012, SCENIHR launched a safety assessment of metal-on-metal joint replacements, and particularly hip implants (hip arthroplasties).
SCENIHR said it was particularly interested in assessing the range of materials used in the implants, the number and severity of adverse events associated with metal-on-metal implants versus those with non-metal-on-metal implants, postmarketing data and the effectiveness of surveillance systems.
Now SCENIHR has published its preliminary opinion based on that investigation, stating that while the products should not be banned, they should be "carefully" considered on a case-by-case basis based on the elevated risks to patients.
However, certain subgroups should entirely avoid using large-headed metal-on-metal implants, the committee wrote. Those groups include young and active men with a large bony femoral head larger than 50 mm, and all women with a femoral head smaller than 50 mm.
Only the most experienced surgeons should perform the procedures, the committee's assessment continued, and patients should be followed up with "rigorously" to determine if revisions are needed.
The opinion is open for comment until 25 April 2014.
SCENIHR Opinion
Tags: Metal-on-Metal Hip Implants, SCENIHR, European Commission, Latest News, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.